{"id":"https://openalex.org/W2111901007","doi":"https://doi.org/10.1345/aph.1m134","title":"Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus","display_name":"Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus","alternate_titles":[],"publication_year":2009,"publication_date":"2009-07-28","ids":{"openalex":"https://openalex.org/W2111901007","doi":"https://doi.org/10.1345/aph.1m134","mag":"2111901007","pmid":"https://pubmed.ncbi.nlm.nih.gov/19638470"},"language":"en","primary_location":{"id":"doi:10.1345/aph.1m134","doi":"https://doi.org/10.1345/aph.1m134","is_oa":false,"landing_page_url":"https://doi.org/10.1345/aph.1m134","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2111901007"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082350484","display_name":"Joshua J. Neumiller","orcid":"https://orcid.org/0000-0002-4734-7402","observed_orcids":["https://orcid.org/0000-0002-4734-7402"]},"institutions":[{"id":"https://openalex.org/I170632171","display_name":"Washington State University Spokane","ror":"https://ror.org/04vfs5h36","country_code":"US","type":"education","lineage":["https://openalex.org/I170632171","https://openalex.org/I72951846"]},{"id":"https://openalex.org/I72951846","display_name":"Washington State University","ror":"https://ror.org/05dk0ce17","country_code":"US","type":"education","lineage":["https://openalex.org/I72951846"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joshua J Neumiller","raw_affiliation_strings":["Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, Spokane, WA","Joshua J Neumiller PharmD CDE CGP FASCP, Assistant Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, Spokane, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, Spokane, WA","institution_ids":["https://openalex.org/I170632171"]},{"raw_affiliation_string":"Joshua J Neumiller PharmD CDE CGP FASCP, Assistant Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, Spokane, WA","institution_ids":["https://openalex.org/I170632171","https://openalex.org/I72951846"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087170338","display_name":"R. Keith Campbell","orcid":"https://orcid.org/0009-0001-9734-1762","observed_orcids":["https://orcid.org/0009-0001-9734-1762"]},"institutions":[{"id":"https://openalex.org/I72951846","display_name":"Washington State University","ror":"https://ror.org/05dk0ce17","country_code":"US","type":"education","lineage":["https://openalex.org/I72951846"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R Keith Campbell","raw_affiliation_strings":["Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, WA","R Keith Campbell BSPharm MBA CDE FASHP FAPhA, Distinguished Professor in Diabetes Care, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, WA","institution_ids":["https://openalex.org/I72951846"]},{"raw_affiliation_string":"R Keith Campbell BSPharm MBA CDE FASHP FAPhA, Distinguished Professor in Diabetes Care, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, WA","institution_ids":["https://openalex.org/I72951846"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":null,"fwci":0.7567,"has_fulltext":false,"cited_by_count":64,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.55411845,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"43","issue":"9","first_page":"1433","last_page":"1444"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9079999923706055},{"id":"https://openalex.org/keywords/glucagon-like-peptide-1-analog","display_name":"glucagon-like peptide-1 analogues","score":0.8240000009536743},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8999999761581421},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8999999761581421},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8989999890327454},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8539999723434448},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9070000052452087},{"id":"https://openalex.org/keywords/beta-cell-function","display_name":"beta-cell function","score":0.9559999704360962},{"id":"https://openalex.org/keywords/metformin-combination-therapy","display_name":"metformin combination therapy","score":0.6790000200271606},{"id":"https://openalex.org/keywords/insulin-glargine","display_name":"insulin glargine","score":0.7400000095367432},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5709999799728394},{"id":"https://openalex.org/keywords/nausea-and-vomiting","display_name":"nausea and vomiting","score":0.5759999752044678}],"concepts":[{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.9924112558364868},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9236893653869629},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.7474555969238281},{"id":"https://openalex.org/C2778881409","wikidata":"https://www.wikidata.org/wiki/Q1420402","display_name":"Incretin","level":4,"score":0.5733665227890015},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5730030536651611},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5107836723327637},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5065807104110718},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.5039235949516296},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.47068315744400024},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.46594297885894775},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4428299069404602},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4272485375404358},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42351436614990234},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.23397153615951538}],"mesh":[{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018849","descriptor_name":"Controlled Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1345/aph.1m134","doi":"https://doi.org/10.1345/aph.1m134","is_oa":false,"landing_page_url":"https://doi.org/10.1345/aph.1m134","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:19638470","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19638470","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Annals of pharmacotherapy","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.925.8968","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.925.8968","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://aop.sagepub.com/content/43/9/1433.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":60,"referenced_works":["https://openalex.org/W1540138335","https://openalex.org/W1590228841","https://openalex.org/W1968676703","https://openalex.org/W1969759659","https://openalex.org/W1969932276","https://openalex.org/W1973328187","https://openalex.org/W1975756049","https://openalex.org/W1977119153","https://openalex.org/W1986331352","https://openalex.org/W1988031087","https://openalex.org/W1989593799","https://openalex.org/W1992966015","https://openalex.org/W2004977380","https://openalex.org/W2005230361","https://openalex.org/W2007436871","https://openalex.org/W2013851956","https://openalex.org/W2016732441","https://openalex.org/W2019002829","https://openalex.org/W2019099090","https://openalex.org/W2023462541","https://openalex.org/W2026171909","https://openalex.org/W2027433835","https://openalex.org/W2030684076","https://openalex.org/W2033072177","https://openalex.org/W2037815969","https://openalex.org/W2043092889","https://openalex.org/W2053138570","https://openalex.org/W2054564814","https://openalex.org/W2063715420","https://openalex.org/W2067710447","https://openalex.org/W2068488844","https://openalex.org/W2071075324","https://openalex.org/W2071835038","https://openalex.org/W2096444181","https://openalex.org/W2098459806","https://openalex.org/W2099819878","https://openalex.org/W2100375415","https://openalex.org/W2101613382","https://openalex.org/W2102400698","https://openalex.org/W2103525547","https://openalex.org/W2108771199","https://openalex.org/W2118889627","https://openalex.org/W2126520659","https://openalex.org/W2128077095","https://openalex.org/W2129449971","https://openalex.org/W2132105666","https://openalex.org/W2133435074","https://openalex.org/W2139366216","https://openalex.org/W2140978079","https://openalex.org/W2141338760","https://openalex.org/W2143752451","https://openalex.org/W2145924144","https://openalex.org/W2146901298","https://openalex.org/W2147817624","https://openalex.org/W2157018205","https://openalex.org/W2164169548","https://openalex.org/W2164961795","https://openalex.org/W2335557701","https://openalex.org/W4234825176","https://openalex.org/W4246288537"],"related_works":["https://openalex.org/W2085673400","https://openalex.org/W1874759440","https://openalex.org/W2133435074","https://openalex.org/W1589544939","https://openalex.org/W2067950322","https://openalex.org/W2124122508","https://openalex.org/W2145946388","https://openalex.org/W2161671847","https://openalex.org/W2139891523","https://openalex.org/W2409727824"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"review":[2],"the":[3,18,38,51,59,84,116,132,187,232,284],"pharmacology,":[4,85],"pharmacokinetics,":[5,86],"efficacy,":[6,87],"and":[7,46,55,68,88,131,157,167,178,184,199,229,259],"safety":[8,89],"of":[9,20,61,90,118,122,147,189,272,286,293],"liraglutide,":[10],"a":[11,98,246],"glucagon-like":[12,40],"peptide":[13,41],"1":[14],"(GLP-1)":[15],"analog":[16,100],"for":[17,34,58,73,105,136,186,249],"treatment":[19,188],"type":[21,190],"2":[22,191],"diabetes":[23],"mellitus.":[24],"DATA":[25,79,94],"SOURCES:":[26],"A":[27],"MEDLINE":[28],"search":[29],"(1966-May":[30],"2009)":[31],"was":[32,265],"conducted":[33],"English-language":[35],"articles":[36],"using":[37],"terms":[39,121],"1,":[42],"incretin":[43],"mimetic,":[44],"NN2211,":[45],"liraglutide.":[47],"Abstracts":[48],"presented":[49],"at":[50],"American":[52],"Diabetes":[53,62],"Association":[54,57],"European":[56],"Study":[60],"annual":[63],"meetings":[64],"in":[65,120,128,158,164,179,238,257,283],"2006,":[66],"2007,":[67],"2008":[69],"were":[70,92],"also":[71,144],"searched":[72],"relevant":[74],"data.":[75],"STUDY":[76],"SELECTION":[77],"AND":[78],"EXTRACTION:":[80],"Articles":[81],"pertinent":[82],"to":[83,153,215],"liraglutide":[91,119,148,170,221,250,264],"reviewed.":[93],"SYNTHESIS:":[95],"Liraglutide":[96,172],"is":[97,222],"GLP-1":[99,276],"with":[101,155,169,181,196,225,254,267,275,290],"pharmacokinetic":[102],"properties":[103],"suitable":[104],"once-daily":[106],"administration.":[107],"Clinical":[108],"trial":[109],"data":[110,160,195,212],"from":[111,204],"large,":[112],"controlled":[113],"studies":[114],"demonstrate":[115],"effectiveness":[117],"hemoglobin":[123],"A(1c)":[124],"(A1C)":[125],"reduction,":[126],"reductions":[127],"body":[129,260],"weight,":[130],"drug's":[133],"low":[134],"risk":[135,292],"hypoglycemic":[137],"events":[138,237],"when":[139,263],"used":[140],"as":[141,176],"monotherapy.":[142],"Data":[143],"support":[145],"benefits":[146,163],"therapy":[149,201,278],"on":[150,213],"beta-cell":[151,165],"responsiveness":[152],"glucose,":[154],"animal":[156],"vitro":[159],"indicating":[161],"potential":[162,280],"mass":[166],"neogenesis":[168],"treatment.":[171],"has":[173],"been":[174],"studied":[175],"monotherapy":[177],"combination":[180],"metformin,":[182],"glimepiride,":[183],"rosiglitazone":[185],"diabetes.":[192],"Additionally,":[193],"comparative":[194],"insulin":[197,273],"glargine":[198],"exenatide":[200],"are":[202],"available":[203],"Phase":[205],"3":[206],"trials":[207],"providing":[208],"practitioners":[209],"valuable":[210],"clinical":[211,217,239,281],"which":[214],"base":[216],"decision":[218],"making.":[219],"Overall,":[220],"well":[223],"tolerated":[224],"dose-dependent":[226],"nausea,":[227],"vomiting,":[228],"diarrhea":[230],"being":[231],"most":[233],"commonly":[234],"reported":[235],"adverse":[236],"trials.":[240],"CONCLUSIONS:":[241],"Once-daily":[242],"administration":[243],"may":[244],"provide":[245],"therapeutic":[247],"advantage":[248],"over":[251],"twice-daily":[252],"exenatide,":[253],"similar":[255],"improvements":[256],"A1C":[258],"weight":[261],"observed":[262],"compared":[266],"exenatide.":[268],"The":[269],"glucose-dependent":[270],"mechanism":[271],"release":[274],"agonist":[277],"holds":[279],"significance":[282],"management":[285],"postprandial":[287],"hyperglycemic":[288],"excursions,":[289],"minimal":[291],"hypoglycemia.":[294]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2111901007","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
